United Therapeutics Corporation (UTHR) gains on deep earnings analysis
United Therapeutics Corporation (UTHR) posted a mixed quarter, missing EPS but beating revenue as shares gained on the session. This deep-dive looks beyond the headline, examining record Tyvaso sales, the Liquidia settlement, margin pressure, pipeline breadth, and why investors focused on growth over the earnings miss.
United Therapeutics Corporation (UTHR) reported a mixed Q3 2026 result, beating revenue expectations with a quarterly record $833 million in sales while EPS came in below estimates at $5.71. Investors ultimately looked past the earnings miss and focused on record Tyvaso demand, a favorable Liquidia settlement, and a pipeline that now spans 14 development programs.
United Therapeutics Corporation (UTHR) gains on Q3 earnings
United Therapeutics Corporation (UTHR) delivered a Q3 2026 revenue beat but missed EPS estimates, creating a mixed earnings picture. Shares initially fell 2.75% in premarket trading, then showed gains during the Nov. 4 session as investors focused on record Tyvaso sales, a favorable Liquidia settlement, and the company’s pipeline.
Key Takeaways
UTHR reported EPS of $5.71, below the $6.01 estimate, while revenue reached $0.83B versus the $0.78B consensus.
Revenue reached a quarterly record of $833M, supported by record Tyvaso revenue of $504M.
Net income was $0.26B, below $0.33B in Q2 2026 and $0.36B in Q4 2025.
Management said the Liquidia settlement removed PH-ILD from the YUTREPIA label and left Tyvaso without direct branded competition on the horizon.
CEO Martine Rothblatt highlighted 14 development programs spanning pulmonary hypertension, pulmonary fibrosis, respiratory devices, and manufactured organ alternatives.
Analyst reaction remained constructive. Cantor raised its price target to $850 from $700, while Leerink Partners and Raymond James also lifted targets.
UTHR Financial Performance: Revenue Beat, EPS Miss
The central result from the UTHR earnings report was a split between sales and profitability. Revenue of $0.83B exceeded the $0.78B estimate. EPS of $5.71, however, missed the $6.01 consensus by $0.30.
Revenue also improved against recent quarters. UTHR reported $0.78B in Q2 2026, $0.78B in Q1, $0.79B in Q4 2025, and $0.80B in Q3 2025. The latest result therefore set a new quarterly revenue record, even as earnings per share remained below recent levels.
The earnings history shows EPS of $7.27 in Q2 2026, $5.82 in Q1, $7.70 in Q4 2025, and $7.16 in Q3 2025. The current $5.71 result sits below each of those recent quarterly figures except for the comparable Q1 2026 result. That makes the EPS miss more important than the headline revenue beat.
Net income followed the same pattern. UTHR reported $0.26B in Q3, compared with $0.33B in Q2, $0.27B in Q1, $0.36B in Q4 2025, and $0.34B in Q3 2025. The company therefore produced stronger sales but lower net income than in several recent periods.
Tyvaso was the standout product. Management reported record Tyvaso revenue of $504M, driven by referrals, patient starts, increased dosing, and physician engagement. Michael Benkowitz said the company received more than 1,000 referrals for a UTHR product in October, the highest monthly total in company history.
The longer-term product mix also shows Tyvaso’s importance. In 2025, Tyvaso generated $1.8782B in revenue, compared with $526.8M for Remodulin, $496.9M for Orenitram, $226.8M for Unituxin, $30M for Adcirca, and $24M from product and service revenue. Q3’s $504M Tyvaso result reinforces the product’s role as UTHR’s commercial growth engine.
For investors, the mechanics are straightforward. Revenue momentum is improving, but the EPS miss and lower net income show that sales growth did not translate into a stronger bottom line this quarter. The company’s growth thesis therefore depends on both Tyvaso expansion and successful launches from its pipeline.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
UTHR shares fell to $584.76 in premarket trading after closing at $601.32 before the report. By 2:30 p.m. ET on Nov. 4, the stock traded at $608.426, up 1.18%. Volume was 561,619 shares, below the average volume of 717,282 shares.
That reversal shows how quickly investors reassessed the quarter. The initial reaction centered on the EPS miss. Later trading gave more weight to the revenue record, Tyvaso demand, and the company’s improved competitive position after its Liquidia settlement.
The analyst consensus remained Buy, with 19 Buy ratings, 11 Holds, and 1 Sell. Recent target actions were mostly constructive, although several firms trimmed targets while keeping positive ratings.
Cantor Fitzgerald analyst Olivia Brayer raised the target to $850 from $700 and kept an Overweight rating. The firm cited the improved competitive backdrop after the Liquidia settlement and the value of UTHR’s broader pipeline, while also noting limited near-term visibility.
Leerink Partners raised its target to $725 from $685 and maintained Outperform. The firm updated its model for stronger Tyvaso growth in PH-ILD and near-term payments tied to the Liquidia litigation resolution.
Raymond James raised its target to $717 from $685 and kept Outperform. By contrast, JPMorgan cut its target to $695 from $710 while maintaining Overweight, and RBC Capital lowered its target to $697 from $708 while maintaining Outperform. The pattern is constructive rather than euphoric, which fits a quarter with strong revenue and a clear EPS shortfall.
Management Commentary: Tyvaso Momentum and Pipeline Expansion
CEO Martine Rothblatt framed the quarter as part of a wider shift in UTHR’s identity. The company is moving beyond its traditional pulmonary hypertension base and building a broader cardiopulmonary and respiratory platform.
“Today, that legacy serves as the foundation for a much bigger UT.” - Martine Rothblatt, Chairperson and CEO, UTHR earnings call
Rothblatt cited 14 programs in development, including nebulized and dry powder therapies, soft mist inhalers, once-daily medicines, and combination products. She also pointed to approximately 1 million people in the US across IPF, PPF, and PH-COPD as the addressable patient populations under development.
“Our strategy is to keep innovating so we can offer more patients the right therapy in the right format at the right time.” - Martine Rothblatt, Chairperson and CEO, UTHR earnings call
President and COO Michael Benkowitz focused on commercial execution. He said earlier investments in sales resources and messaging were expanding physician engagement and disease awareness across PAH and PH-ILD.
“Our base business is performing, our commercial strategy is working, our competitive position is strong, and we expect to enter 2027 with substantially more momentum than we had entering 2026.” - Michael Benkowitz, President and COO, UTHR earnings call
The Liquidia settlement was central to that outlook. Management said PH-ILD would be removed from the YUTREPIA label, Liquidia would be barred from promoting the indication, and off-label encouragement would be prohibited. Benkowitz also stressed that near-term switches from YUTREPIA to Tyvaso should remain moderate because the settlement did not require existing patients to change treatment.
Analyst Q&A Highlights from the UTHR Earnings Call
The Q&A focused on whether the Liquidia settlement would create an immediate commercial lift or a slower increase in new prescriptions.
“What are sort of your expectations of current YUTREPIA patients switching over?” - Joseph Thome, TD Cowen, UTHR earnings call
Benkowitz pushed back on the idea of a rapid forced conversion. He said physicians and patients would decide whether to move existing YUTREPIA patients to Tyvaso DPI. His answer shifted the opportunity away from a one-time switch event and toward new prescriptions in the under-penetrated PH-ILD market.
“If a patient's doing well on YUTREPIA, there's not really going to, I think, be a push on the part of doctors to switch patients over.” - Michael Benkowitz, President and COO, UTHR earnings call
Cantor analyst Olivia Brayer pressed management on the timing of any PH-ILD acceleration and whether the benefit would show up in Q4 or after patients reached January reauthorization points.
“Are you guys actually seeing any acceleration in new starts on Tyvaso in the fourth quarter just on the back of that settlement?” - Olivia Brayer, Cantor Fitzgerald, UTHR earnings call
Brayer also asked about the soft mist inhaler filing timeline and the product’s potential in PH-COPD. Those questions show where analysts are placing the next layer of value: Tyvaso’s immediate commercial momentum, followed by the timing and profile of new respiratory products.
United Therapeutics Corporation posted a strong revenue quarter, but the $5.71 EPS result and $0.26B net income show that profitability remains the weak point in the latest UTHR earnings report. Tyvaso demand, the Liquidia settlement, and 14 development programs support the long-term growth case, while the immediate investment debate centers on whether those assets can convert into sustained earnings growth.
+Did United Therapeutics (UTHR) beat or miss earnings in Q3 2026?
United Therapeutics beat revenue expectations but missed on earnings per share. Revenue was $833 million versus the $780 million consensus, while EPS came in at $5.71 versus the $6.01 estimate.
+Why did UTHR stock recover after the initial post-earnings drop?
The stock initially fell on the EPS miss, then recovered as investors focused on the revenue beat and record Tyvaso sales. Shares were down 2.75% premarket before trading up 1.18% to $608.426 by 2:30 p.m. ET on Nov. 4.
+How important was Tyvaso in United Therapeutics' Q3 results?
Tyvaso was the standout product, generating a record $504 million in quarterly revenue. Management said growth came from referrals, patient starts, increased dosing, and physician engagement.
+What did the Liquidia settlement mean for United Therapeutics investors?
Management said the settlement removed PH-ILD from the YUTREPIA label and left Tyvaso without direct branded competition on the horizon. That improved the competitive backdrop and helped support analyst optimism on the stock.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on UTHR?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.